8-K: Supernus Announces Positive Phase 2a Data for SPN-820 in Major Depressive Disorder

Supernus Pharmaceuticals reports promising results from a Phase 2a study of SPN-820, showing rapid and substantial reduction in depressive symptoms in adults with major depressive disorder.

Summary

• Supernus Pharmaceuticals announced positive data from its Phase 2a open-label clinical study of SPN-820 in adults with major depressive disorder.
• The study evaluated the safety and tolerability of SPN-820 2400 mg given once every 3 days as an add-on to existing antidepressant therapy.
• The study included 40 participants, with 38 completing the 10-day treatment period.
• Results showed a clinically meaningful improvement of 6.1 at two hours and 9.6 at Day 10 on the Hamilton Depression Rating Scale-6 Items (HAM-D6).
• The Montgomery-Åsberg Depression Rating Scale (MADRS) total score improved by 16.6 at four hours and 22.9 at Day 10.
• Suicidal ideation decreased by 80%, from 12.5% at baseline to 2.6% at Day 10.
• SPN-820 was well-tolerated with a low discontinuation rate of 2.5% due to adverse events.
• The most common adverse events were headache, nausea, somnolence, and dizziness.

Sentiment

Score: 8

Explanation: The document presents very positive results from the Phase 2a study, with strong efficacy and tolerability data. The reduction in suicidal ideation is particularly encouraging. The company's management also expresses optimism about the potential of SPN-820. However, the study is still in early stages and further trials are needed.

Positives

• The study showed a rapid onset of action for SPN-820, with improvements seen as early as two hours after administration.
• The reduction in suicidal ideation is a significant positive finding.
• The drug was well-tolerated with a low discontinuation rate, suggesting a favorable safety profile.
• The results suggest SPN-820 has the potential to be a novel treatment option for depression.

Negatives

• The most common adverse events included headache, nausea, somnolence, and dizziness, which may be a concern for some patients.
• Additional adverse events such as cognitive disorder, dry mouth, fatigue, nasal congestion, and paresthesia oral were also observed.

Risks

• The study was an open-label Phase 2a study, which may have limitations compared to a randomized, double-blind, placebo-controlled study.
• The Phase 2b study is still ongoing, and the results may differ from the Phase 2a study.
• The company's ability to obtain regulatory approvals for SPN-820 is not guaranteed.
• The company faces risks related to commercializing its products and competition in the market.

Future Outlook

The company expects to complete enrollment in the Phase 2b study in November of this year, with topline results expected in the first half of 2025. The company is optimistic about the potential of SPN-820 as a novel treatment for depression.

Management Comments

• Jack Khattar, President and CEO of Supernus, stated that the Phase 2a data underscores their belief that SPN-820 has the potential as a novel treatment option for patients with depression.
• Mr. Khattar also noted the opportunity to decrease symptoms quickly and without certain burdensome side effects.

Industry Context

This announcement is significant in the context of the ongoing need for new and effective treatments for depression, particularly those with a rapid onset of action. The novel mechanism of action of SPN-820, targeting mTORC1, differentiates it from existing antidepressants.

Comparison to Industry Standards

• The rapid onset of action observed with SPN-820, with improvements seen within hours, is a notable advantage compared to many traditional antidepressants that can take weeks to show effects.
• The 80% reduction in suicidal ideation is a significant finding, as many existing treatments do not directly address this critical symptom.
• The tolerability profile of SPN-820 appears favorable compared to some other antidepressants that are associated with more significant side effects.
• Companies like Sage Therapeutics and Axsome Therapeutics are also developing novel treatments for depression, and the results of the Phase 2b study will be important in assessing SPN-820's competitive position.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with major depressive disorder may benefit from a new treatment option with a rapid onset of action.
• Employees of Supernus may be motivated by the positive progress of SPN-820.
• The company's success could lead to increased revenue and growth.

Next Steps

• The company will complete enrollment in the Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression in November of this year.
• Topline results from the Phase 2b study are expected in the first half of 2025.

Key Dates

Keywords

SPN-820, Major Depressive Disorder, Depression, Clinical Trial, Phase 2a, mTORC1, Antidepressant, CNS, Supernus Pharmaceuticals, HAM-D6, MADRS